The arrival of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 receptor medication suggests to provide impressive improvements in weight reduction compared to previous therapies. Initial research studies